William Blair Reaffirms “Market Perform” Rating for Zoetis (NYSE:ZTS)

Zoetis (NYSE:ZTS)‘s stock had its “market perform” rating reiterated by investment analysts at William Blair in a research report issued on Thursday,Benzinga reports.

Several other research analysts have also recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. HSBC cut their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Finally, Citigroup lowered their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $118.33.

Zoetis Stock Up 3.1%

NYSE ZTS traded up $2.31 on Thursday, reaching $76.70. 7,813,073 shares of the stock traded hands, compared to its average volume of 5,676,100. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a fifty day moving average price of $76.78 and a 200-day moving average price of $101.29. The company has a market cap of $32.16 billion, a price-to-earnings ratio of 12.87, a PEG ratio of 1.19 and a beta of 0.74. Zoetis has a 12 month low of $71.47 and a 12 month high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts forecast that Zoetis will post 6.87 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 11,650 shares of company stock worth $886,384 over the last three months. Corporate insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System acquired a new position in shares of Zoetis in the 1st quarter valued at $2,542,000. Deutsche Bank AG raised its holdings in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after buying an additional 891,921 shares during the period. Pincus Capital Management LP purchased a new stake in Zoetis in the 4th quarter valued at about $2,109,000. Highbridge Capital Management LLC acquired a new position in Zoetis in the fourth quarter valued at about $7,004,000. Finally, Swedbank AB lifted its position in Zoetis by 9.9% in the first quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock valued at $355,126,000 after buying an additional 269,610 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 consensus range and up from $1.76 a year earlier. The earnings beat is likely the primary catalyst supporting the stock. Zoetis Q2 Earnings Beat
• Positive Sentiment: The company maintained strong profitability, reporting a 27.8% net margin and 66.85% return on equity. Its earnings growth despite largely flat revenue may reassure investors about cost management and operating efficiency. Zoetis Earnings Report
• Neutral Sentiment: Zoetis appointed Jay Saccaro as chief financial officer and chief operating officer. The expanded leadership role could improve financial and operational coordination, but investors may wait for more details on his priorities and expected impact. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Management cut fiscal 2026 adjusted EPS guidance to $6.15–$6.25, well below the roughly $6.87 analyst consensus, and reduced revenue guidance to $9.1–$9.3 billion versus approximately $9.8 billion expected. Zoetis Cuts Fiscal 2026 Outlook
• Negative Sentiment: Quarterly revenue declined 0.2% year over year, while softer U.S. pet-healthcare demand, fewer veterinary visits and more price-sensitive customers remain concerns for companion-animal products. Pet Healthcare Demand Slows

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.